Clcn7F318L/+ as a new mouse model of Albers-Schönberg disease by Caetano-Lopes, J. et al.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Clcn7
F318L/+ 
as a new mouse model of Albers-Schönberg disease
Caetano-Lopes J
1,2
, Lessard SG
1,2
, Hann S
1,2
, Espinoza K
3
, Kang KS
4
, Lim KE
4
, Horan DJ
4
,
Noonan HR
5
, Hu D
6
, Baron R
6
, Robling AG
4
, Warman ML
1,2,3
.
1. Orthopaedic Research Laboratories, Boston Children's Hospital, Boston, MA, USA.
2. Department of Genetics, Harvard Medical School, Boston, MA, USA.
3. Howard Hughes Medical Institute, Boston Children’s Hospital, Boston, MA, USA.
4. Department of Anatomy and Cell Biology, Indiana University School of Medicine,
Indianapolis, IN, USA. 
5. BBS Program, Harvard Medical School, Boston, MA, USA.
6. Division of Bone and Mineral Research, Harvard School of Dental Medicine, Boston,
Massachusetts, USA. 
Corresponding author: 
Matthew L. Warman 
Boston Children's Hospital 
Orthopaedic Research Laboratories 
Enders 250 
320 Longwood Ave 
Boston, MA, 02115 
(617) 919-2371 
email: matthew.warman@childrens.harvard.edu 
ACCEPTED MANUSCRIPT
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Caetano-Lopes, J., Lessard, S. G., Hann, S., Espinoza, K., Kang, K. S., Lim, K. E., … Warman, M. L. (2017). Clcn7F318L/+ as a 
new mouse model of Albers-Schönberg disease. Bone. https://doi.org/10.1016/j.bone.2017.09.007
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 2 
Abstract 
Dominant negative mutations in CLCN7, which encodes a homodimeric chloride channel 
needed for matrix acidification by osteoclasts, cause Albers-Schönberg disease (also known 
as autosomal dominant osteopetrosis type 2). More than 25 different CLCN7 mutations have 
been identified in patients affected with Albers-Schönberg disease, but only one mutation 
(Clcn7
G213R
) has been introduced in mice to create an animal model of this disease.  Here we 
describe a mouse with a different osteopetrosis-causing mutation (Clcn7
F318L
). Compared to 
Clcn7
+/+
 mice, 12-week-old Clcn7
F318L/+
 mice have significantly increased trabecular bone 
volume, consistent with Clcn7
F318L
 acting as a dominant negative mutation. Clcn7
F318L/F318L
 
and Clcn7
F318L/G213R
 mice die by 1 month of age and resemble Clcn7 knockout mice, which 
indicate that p.F318L mutant protein is non-functional and p.F318L and p.G213R mutant 
proteins do not complement one another. Since it has been reported that treatment with 
interferon gamma (IFN-G) improves bone properties in Clcn7
G213R/+
 mice, we treated 
Clcn7
F318L/+
 mice with IFN-G and observed a decrease in osteoclast number and mineral 
apposition rate, but no overall improvement in bone properties.  Our results suggest that the 
benefits of IFN-G therapy in patients with Albers-Schönberg disease may be mutation-
specific.  
 
Keywords 
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1. Introduction 
Osteopetrosis is a genetically heterogeneous disease characterized by defective bone 
resorption, increased bone density, and skeletal fragility. Several types of osteopetrosis have 
been described and most are autosomal recessive [1]. An autosomal dominant form of 
osteopetrosis, also known as Albers-Schönberg disease, occurs in ~ 1:20,000 persons [2, 3]. 
Symptoms and signs of Albers-Schönberg disease generally appear in childhood or 
adolescence, and there is wide phenotypic variability within and across families. The 
phenotype in persons with Albers-Schönberg disease can cause debilitating problems and 
worsen over time, and no beneficial pharmacological therapy is currently available [3-5].  
Albers-Schönberg disease is caused by dominant negative (i.e., antimorphic) mutations in 
CLCN7, the gene encoding the homodimeric chloride channel 7 (CLC-7). This channel 
functions as a slow voltage-gated 2Cl
-
/1H
+
 exchanger [6, 7], and gating depends on 
conformational changes that are communicated from one subunit to the other in the dimer [8]. 
In osteoclasts, CLC-7 dimers transport chloride ions into the resorption lacunae. Complete 
deficiency of CLC-7 causes a severe form of autosomal recessive ostepetrosis by making 
osteoclasts unable to resorb bone. Heterozygous CLCN7 mutations that produce a mutant 
protein, which interferes with the function of wildtype protein, cause Albers-Schönberg 
disease. More than 25 different heterozygous mutations that cause Albers-Schönberg disease 
have been identified [9].  
In 2014, Alam et al [10] described mice with a Clcn7 knockin allele (Clcn7
G213R
), which is 
the most common mutation reported in patients with Albers-Schönberg disease [11]. Mice 
homozygous for Clcn7
G213R
 had a severe osteopetrotic phenotype and died weeks after birth, 
whereas heterozygous mice (i.e., Clcn7
G213R/+
) had a phenotype that resembled Albers-
Schönberg disease, including increased areal BMD, increased BV/TV, and increased 
osteoclast numbers with reduced activity [10]. When the mutant allele was crossed into 
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different genetic backgrounds, the highest percent increase in BV/TV compared to controls 
was found with the 129S1 background, followed by DBA/D2, C57BL/6J and Balb/c 
backgrounds [12]. Since interferon gamma (IFN-G) has been reported to benefit some 
patients with recessive forms of osteopetrosis [13], this therapy was evaluated in  
Clcn7
G213R/+
 mice. Thrice weekly IFN-G injection in Clcn7
G213R/+ 
mice on the 129S1 
background, from 4 to 12 weeks of age, significantly reduced trabecular bone BV/TV; one 
reason for this improvement seemed to be improved osteoclast function as indicated by 
increase in the serum CTX/TRAPc5b ratio [14].   
We created mice with a different osteopetrosis-associated Clcn7 knockin mutation 
(Clcn7
F318L
). Here we describe the phenotype of mice with Clcn7
F318L 
alleles and their 
response to IFN-G therapy. 
  
2. Methods 
The Institutional Animal Care and Use Committee at Boston Children’s Hospital approved 
this work. All experiments were conducted in accordance with the National Institutes of 
Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 
1978). 
 
2.1 Creation of mice with a Clcn7
F318L
 knockin allele 
A 779-basepair fragment containing coding exon 11 of Clcn7 was PCR amplified using 
JM8A3.N1 mouse embryonic stem (ES) cell [15] genomic DNA as template. The amplimer 
was subcloned into pBluescript II KS+ (pBSII KS+) and a p.F318L missense mutation was 
introduced by site directed mutagenesis (Agilent Technologies, CA, USA). Note the actual 
mouse mutation is p.F316L, but we use the human protein nomenclature when referring to 
this allele throughout this manuscript. Using the same stem cell genomic DNA as template, 
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4.5 kb upstream and 2.5 kb downstream targeting arms were PCR amplified (5’ arm: P1- 
AGAGTTTCTCTGTGTAGCCATTGTT, P2- ACTGAAGAAAGCACAGTGAGCG; 3’ 
arm: P3- CCCTTAGGAACTTCGCATAGTTAGC, P4- CTGGAGTGGGTAGGACAT). The 
targeting arms along with the p.F318L mutation containing fragment, were combined by in-
fusion cloning (Clontech, CA, USA) with a floxed neomycin selection cassette and a 
thymidine kinase selection cassette to produce the targeting vector depicted in Figure 1A. 
Homologous recombination of the linearized construct was performed in JM8A3.N1 ES cells 
[15] using ganciclovir and neomycin selection. Correctly targeted ES cells were identified by 
long-range PCR across both homology arms (5’end: P5- GAGCAGGAGTTACAGCTGGG, 
P6- GCTCGACTAGAGCTTGCGGA; 3’end: P7- CCACTTGTGTAGCGCCAAG; P8- 
TCCCCACACACCTACTGACA). A correctly targeted clone with a normal karyotype was 
introduced into C57BL/6J blastocysts to produce chimeric mice, which were then crossed to 
C57BL/6J mice to attain germline transmission of the p.F318L mutation. Tg(Gata1-cre)1Sho 
[16] mice were then used to Cre-excise the neomycin selection cassette. The final Clcn7
F318L
 
allele used in these studies is depicted in Figure 1A. 
 
2.2 Animal breeding, maintenance, and genotyping 
Clcn7
F318L/+ 
mice were intercrossed, crossed with C57BL/6J mice, or crossed with 
Clcn7
G213R/+ 
mice [10]. Offspring were tail clipped at 10 days of age, weaned before 28 days 
of age and then housed with same-sex littermates. Tail snip DNA was recovered using the 
HotSHOT method [17]. For genotyping the Clcn7
F318L
 allele, PCR primers (P9: 
GCTCCTCAGACGCATGGAAT and P10: AGAAAACAGGAGAGCTGGCA), which 
generate a 407 bp amplimer for the wildtype allele and a 530 bp amplimer for the Clcn7
F318L
 
allele (Figure 1B) were used. Clcn7
G213R
 genotyping was performed as previously described 
[10]. 
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2.3 Phenotypic assessment 
Twenty-one day old mice were sacrificed using CO2 followed by cervical dislocation.  
Prior to sacrifice, animals were weighed and bone mineral density (BMD) was measured with 
the Piximus II dual energy X-ray absorptiometer (GE Lunar, Madison, WI). After sacrifice, 
femurs and 4
th
 lumbar vertebra were removed, dissected free of soft tissue, and either placed 
in 4% paraformaldehyde (PFA) at room temperature for micro-computed tomography (CT) 
and histomorphometry analysis or wrapped in saline soaked gauze and frozen at -20°C for 
biomechanical measurements. 
Twelve-week-old mice, which had received intraperitoneal (IP) Calcein (Sigma, MO, 
USA; 10mg/Kg) when 11-weeks-old, and IP Alizarin complexone (Sigma, MO, USA; 
20mg/Kg) when 11-weeks and 4-days old as previously described [18], were fasted for 6 
hours prior to sacrifice. Prior to euthanasia by CO2 and cervical dislocation, the animals were 
weighed and had their BMD measured. After euthanasia, cardiac puncture was performed to 
collect blood for serum markers of bone anabolism and catabolism. Femora and 4
th
 lumbar 
vertebrae were removed and processed as described earlier.  
 
2.4 IFN-G treatment 
Wild type (i.e., Clcn7
+/+
) and mutant (i.e., Clcn7
F318L/+
 and/or Clcn7
F318L/F318L
) mice were 
randomized to receive subcutaneous injection of vehicle (50 µl of 0.1% BSA in PBS) or 
recombinant mouse IFN-G (stock number 485-MI, R&D Systems, MN, USA; 37.5 
g/kg/dose of a 10 µg/ml stock solution). When therapy began at P10, injections were given 
5 times/week until P22 (10 doses total). Mice were then sacrificed. When therapy began at 4 
weeks of age, injections were given 3 times/week until 12 weeks of age. Mice were then 
sacrificed. 
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2.5 RT-PCR to assess splicing of the Clcn7
F318L
 allele 
mRNA was recovered from Clcn7
+/+
, Clcn7
F318L/+
 and Clcn7
F318L/F318L 
3-week-old mouse 
tibiae after the bone marrow was removed. Reverse transcription cDNA synthesis was 
performed using 200 ng of RNA from each sample with the ProtoScript II First Strand cDNA 
Synthesis Kit (New England Biolabs, MA, USA), according to the manufacturer’s 
instructions. Primers located in exons 5 and 13 were used to amplify Clcn7 cDNA. (Forward 
primer: CCGCGTCATCAAGGACAACAT, reverse primer: 
TGGTGTAGGCCATTTTCTCTG). Amplimers were separated by gel electrophoresis to 
determine if splicing of the Clcn7
F318L
 allele was the same as that of the Clcn7
+
 allele. 
 
2.6 Droplet digital PCR to assess relative abundance of Clcn7
F318L
 mRNA in heterozygous 
mice 
RNA was recovered from liver, kidney and marrow-free tibia of 3-week-old Clcn7
+/+
, 
Clcn7
F318L/+
, and Clcn7
F318L/F318L 
mice and used to prepare cDNA as described above. A 
forward primer located in exon 10 and a reverse primer spanning the junction of exons 12 
and 13 were used to amplify Clcn7 transcript (ddPCR-F: AGCTGGTGTATCTGCTGCATT; 
ddPCR-R: TGGTGTAGGCCATTTTCTCG, 233bp). Fluorescent probes that distinguish 
Clcn7
F318L 
amplimer (56-FAM/AGAGGGCGCCTCCCTCTGGAATCA/3IABkFQ) from 
Clcn7
+
 amplimer (5HEX/AAGAGGGCGCCTCCTTCTGGAATCAGT/3IABkFQ) were 
purchased (Integrated DNA Technologies, IA, USA). Prior to performing ddPCR, cDNA 
concentrations were adjusted to 10 ng/l in water.  Thirty ng of cDNA template was used per 
reaction with the BioRad Supermix for Probes protocol. Droplets were created on a BioRad 
automatic droplet generator and PCR (95C/10mins; 94C/30s; 60C/60s; 72C/20s; 40 
cycles; 98C/10mins – cycling ramp speed was set to 1.2C/s) was performed on Eppendorf 
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 8 
ep gradient S machine thermocycler (Eppendorf, Germany). Droplets containing Clcn7
+
 or 
Clcn7
F318L
 amplimers were counted on a BioRad QX200 sample reader and analysed with 
Quantasoft software (BioRad, CA, USA).   
 
2.7 Immunofluorescence detection of CLC-7 protein 
Long bones collected from P18 Clcn7
+/+
 and Clcn7
F318L/F318L
 mice were briefly cleaned in 
ethanol before their marrow cavities were flushed with Hank’s Balanced Salt Solution 
(HBSS, Gibco, MA, USA) to collect bone marrow. Red blood cells in the bone marrow 
samples were lysed using RBC lysis buffer (Roche, IN, USA) and the remaining cells were 
plated in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, MA, USA) supplemented 
with 10% fetal bovine serum (FBS, Gibco, MA, USA), 100U/mL penicillin/streptomycin 
(Gibco, MA, USA) and 40ng/mL macrophage colony-stimulating factor (M-CSF, Peprotech, 
UK) on 6-well plates (Denville, MA, USA), and kept overnight in a cell culture incubator at 
37C in 5% CO2. The following day, non-adherent cells were collected, centrifuged at 400 x 
g for 10 minutes, resuspended in 2 ml of DMEM, counted on a hemocytometer, and plated at 
12,000 cells per chamber slide (Corning, NY, USA) in DMEM, with 10% FBS, 100U/mL 
penicillin/streptomycin, and 40ng/mL M-CSF for 2 additional days. Cells were then fixed in 
4% PFA and incubated with rabbit anti-CLC-7 polyclonal antibody (stock number sc-28755, 
Santa Cruz Biotechnology, TX, USA; diluted 1:100 in PBS/BSA/Tween, which contains 1% 
BSA and 0.1% Tween20) for 1 hour at room temperature and then overnight at 4C. After 3 x 
10 minute washes in PBS/BSA/Tween, a FITC-labeled anti-rabbit IgG goat monoclonal 
antibody (stock number sc-2012, Santa Cruz Biotechnology, TX, USA; diluted 1:300 in 
PBS/BSA/Tween) was added to the chamber slide and incubated for 1 hour at room 
temperature. Slides that had only been incubated with FITC-labeled anti-rabbit IgG goat 
monoclonal antibody served as a negative control. After another 3 x 10 minute washes in 
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PBS/BSA/Tween the slides were air-dried, stained with Hoechst 33342 (LifeTechnologies, 
MA, USA) to visualize nuclei, and cover slipped. Fluorescence images were captured on a 
Nikon upright fluorescence microscope (Nikon, NY, USA) at a magnification of 400X.   
 
2.8 BMD measurements 
Whole body scanning was performed using a Piximus II dual energy X-ray absorptiometer 
(GE Lunar, Madison, WI) with 0.18mm x 0.18mm resolution. The machine was calibrated 
before each scanning session using a phantom supplied by the manufacturer. The scan was 
performed with the mice in a prone position under 2.5% isoflurane (Baxter, IL, USA) 
anesthesia, with each limb spread on a plastic tray. Measurements of BMD (g/cm
2
) and bone 
mineral content (BMC, g) were obtained from the whole-body data after excluding the 
calvarium, mandible and teeth. 
 
2.9 CT measurements  
Femoral midshaft cortical bone, distal femur trabecular bone, and 4
th
 lumbar vertebra were 
scanned on a Scanco CT-35 specimen scanner (Scanco Medical AG, Switzerland) as 
previously described [19, 20]. Briefly, the tomography parameters used were as follows: 50 
kV, 120 mA, 151-ms integration time, and 10-μm voxel resolution. Morphometric measures 
included trabecular bone volume fraction (BV/TV, %), trabecular number (Tb.N, 1/mm), 
trabecular thickness (Tb.Th, mm), trabecular separation (Tb.Sp, mm), trabecular bone 
mineral content (BMC, mgHA), cortical area fraction (Ct.Ar/Tt.Ar, %) and cortical thickness 
(Ct.Th, mm) [21].  
 
2.10 Histomorphometry measurements  
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At the time of sacrifice, femurs were collected from 7-10 male 12-week-old Clcn7
+/+
, 
Clcn7
F318L/+ 
and IFN-G treated Clcn7
F318L/+ 
mice for histomorphometric analysis. Osteoblast 
and osteoclast numbers and density, and dynamic bone formation parameters, were measured 
using standard procedures recommended by the American Society of Bone and Mineral 
Research (ASBMR) histomorphometry committee [22].  
 
2.11 Three-point bending test 
Femur biomechanical studies were performed as previously described [19, 20] using a 
TestResources 100 Series electromechanical test machine (TestResources, Inc., Shakopee, 
MN, USA) with a force resolution of 0.005N. Femoral diaphyses were loaded to failure in a 
three-point bending apparatus, using a cross-head speed of 0.2mm/s, during which force and 
displacement measurements were collected every 0.005s. Lower supports were positioned 8.2 
mm apart.  From the force-displacement curve, yield force (N), stiffness (N/mm), ultimate 
force (N) and energy to ultimate force (mJ) were calculated [19, 20]. 
 
2.12 Assays for anabolic and catabolic bone markers, and for IFN-G levels, in serum 
Whole blood collected by cardiac puncture was placed in Serum Separator BD Microgard 
tubes (BD, Franklin Lakes, NJ), centrifuged at 1723 x g for 15 min at 4C. The separated 
serum was recovered and stored at -80°C. Serum levels of collagen type I cross-linked C-
telopeptide (CTX-I), tartrate-resistant acid phosphatase 5b isoform (TRAcP 5b) and 
procollagen type 1 N-terminal propeptide (P1NP) were measured by enzyme-linked 
immunosorbent assay (ELISA) according to the manufacturers’ instructions (kit numbers 
AC-06F1, SB-TR103 and AC-33F1, respectively; Immunodiagnostics Systems, UK).   
Ten 8-week-old female C57BL/6J mice were randomized to receive a single subcutaneous 
injection of either vehicle or mouse IFN-G (37.5 µg/kg). Two hours later the animals were 
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euthanized by CO2, blood was collected by cardiac puncture, and serum separated as 
described above. Serum concentration of mouse IFN-G was measured using the Quantikine 
IFN-gamma ELISA kit (kit number MIF00; R&D Systems, MN, USA). 
 
2.13 Statistical analyses 
Statistical analyses were performed using SPSS Statistics 23.0 (IBM). Continuous 
variables were expressed as mean ± 1 standard deviation (±1SD). Multiple groups were 
compared using analysis of variance (ANOVA) test followed by Bonferroni’s multiple 
comparison test. Statistical significance was considered when p-values were ≤ 0.05. 
 
3. Results 
3.1 The Clcn7
F318L
 allele acts as a loss-of-function allele when either homozygous or 
compound heterozygous with the Clcn7
G213R
 allele, and as a dominant negative allele when 
heterozygous with a Clcn7
+
 allele.    
 
 
Clcn7
F318L/+ 
mice are viable and fertile. When intercrossed, Clcn7
F318L/F318L
 offspring are 
born at expected Mendelian frequencies, but die when ~ 1 month of age. Homozygous 
mutant offspring are runted and do not have tooth eruption, recapitulating the phenotype seen 
in mice with knockout alleles in Clcn7 (i.e., Clcn7
-/-
) that fail to produce protein [23]. 
Therefore, to determine whether the Clcn7
F318L
 knockin allele is capable of producing a 
mutant protein, we performed 3 different assays. First, we used RT-PCR with a primer-pair 
anchored 5 exons upstream of the intron with the residual loxP site and 2 exons downstream 
of the missense mutation containing exon to determine if the Clcn7
F318L
 allele is spliced 
normally. We observed the same sized RT-PCR product in wildtype, heterozygous, and 
homozygous mice, consistent with the knockin allele having normal mRNA splicing (Figure 
1D). Second, we quantified the amount of wildtype and mutant transcript expressed in 
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heterozygous mice using droplet digital PCR. We observed equal numbers of wildtype and 
mutant transcripts in cDNA from bone (Figure 1E), kidney and liver (data not shown). Third, 
we used an anti-CLC-7 antibody to detect protein in cultured bone marrow cells. We 
observed similar immunofluorescence in cells from Clcn7
+/+ 
and Clcn7
F318L/F318L
 mice
 
(Figure 
1F). Taken together, these data indicate that the Clcn7
F318L
 allele is normally expressed and 
translated into protein. Therefore, mutant protein is produced but is non-functional. 
We next crossed Clcn7
F318L/+
 mice with Clcn7
G213R/+
 mice and generated compound 
heterozygous offspring to determine if the two mutant proteins could complement each other. 
Clcn7
F318L/G213R 
mice lack tooth eruption, are runted, and die by ~ 1 month of age (data not 
shown), just like the Clcn7
F318L/F318L
 mice. Therefore, there is no evidence of 
complementation. 
We next turned our attention to Clcn7
F318L/+
 mice. When examined at 12 weeks of age, we 
found a slight increase in BMD in males Clcn7
F318L/+
 mice compared to Clcn7
+/+
 mice. The 
most significant CT differences we observed in male and female Clcn7F318L/+ mice 
compared to Clcn7
+/+
 mice were in trabecular bone (measured both in the femur (Figure 2) 
and vertebra (data not shown)). Only male Clcn7
F318L/+
 mice showed differences for cortical 
bone parameters and three-point bending assays of bone strength when compared to Clcn7
+/+
 
mice (Figure 2).  
 
3.2 Only Clcn7
F318L/F318L
 and Clcn7
F318L/G213R
 mice have obvious skeletal phenotypes at 3 
weeks of age.  
 
To determine whether it is possible to consistently observe effects of the Clcn7
F318L
 allele 
in younger animals, we performed DEXA, CT and three-point bending tests on Clcn7+/+, 
Clcn7
F318L/+ 
and Clcn7
F318L/F318L
 mice at 3 weeks of age. Clcn7
F318L/F318L
 mice were 
significantly smaller and had greater BMD than Clcn7
F318L/+
 and Clcn7
+/+
 mice, as measured 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 13 
by DEXA (p<0.05, Figure 3). No significant differences were observed between 3-week-old 
Clcn7
F318L/+ 
and Clcn7
+/+ 
mice.  Therefore, the effectiveness of any therapeutic intervention 
will not be detected by µCT in 3-week-old Clcn7
F318L/+
 mice. 
 
3.3 Interferon-gamma therapy did not reduce the trabecular bone volume in Clcn7
F318L/+
 mice 
It has previously been reported that IFN-G therapy benefitted some patients with 
autosomal recessive forms of osteopetrosis [13] as well as the Clcn7
G213R/+ 
mouse model of 
Albers-Schönberg disease [14]. IFN-G is only FDA approved for the treatment of autosomal 
recessive malignant osteopetrosis, but it may be used “off-label” in patients with Albers-
Schönberg disease. Therefore, we treated Clcn7
F318L/+
 mice from 4 to 12 weeks of age, using 
an agent and dosing schedule that improved skeletal properties and markers of bone turnover 
in Clcn7
G213R/+
 mice [14]. We confirmed the bioavailability of IFN-G by measuring serum 
levels 2 hours after subcutaneous injection. Mice that received IFN-G had orders-of-
magnitude fold-increases in serum levels compared to vehicle-treated mice (p<0.0001). As 
previously reported [14] for Clcn7
G213R/+
 mice that received IFN-G, we also observed no 
adverse effects of IFN-G in Clcn7
F318L/+
 mice. At the end of the experiment, the average 
weight of mice receiving IFN-G did not significantly differ from that of mice receiving 
vehicle (Figure 4). However, treatment with IFN-G was not associated with a change in 
tBMD or rabecular bone BV/TV (Figure 4). 
We also administered IFN-G to Clcn7
F318L/F318L
 mice beginning when they were 11 days 
of age. However, rather than benefitting these animals, we observed that these mice died 
before the protocol could be completed, whereas vehicle treated mice did not.    
 
3.4 Clcn7
F318L/+
 mice have increased osteoclast number, which is reduced by interferon-
gamma therapy. 
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Histomorphometry, which was only performed in male mice, revealed more osteoclasts 
per bone perimeter and surface area in Clcn7
F318L/+
 mice compared to Clcn7
+/+
 mice. 
Consistent with this observation both Clcn7
F318L/+
 male and female mice had increased serum 
TRAPc5b compared to Clcn7
+/+
 littermates. 
Decreased numbers of osteoclasts per bone perimeter and per surface area were observed, 
as was decreased serum TRAcP5b, in IFN-G treated Clcn7
F318L/+
 mice compared to vehicle 
treated Clcn7
F318L/+
 mice (Figure 5). However, the IFN-G effect on osteoclasts was not 
associated with a change in trabecular bone BV/TV (Figure 4), perhaps because IFN-G 
treatment also modestly lowered BFR/BV in Clcn7
F318L/+
 mice (Figure 5). 
 
 
 
4. Discussion 
Here we describe a second mouse model of Albers-Schönberg disease.  More than 25 
different causal mutations have been identified in patients and ex vivo studies suggest that 
mutations may negatively impact CLC-7 channel function via different mechanisms [6]. 
Consequently, having more than one animal model makes it possible to ask whether an 
intervention that is beneficial for one mutation could have broad benefit. 
The use of an allelic spectrum of disease-causing mutations when searching for disease-
modifying drugs has already been demonstrated for other diseases, such as osteogenesis 
imperfecta [18, 24-30] and cystic fibrosis [31]. Six classes of mutations have been reported in 
the gene responsible for causing cystic fibrosis based on the effect of the mutation of protein 
synthesis, trafficking, and function [31]. In the case of cystic fibrosis, which is associated 
with thousands of different disease-causing mutations in CFTR, drugs that significantly help 
patients with one class of mutations may be ineffective in patients with other classes. Here, 
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we may have observed a similar difference in responsiveness to IFN-G between mice with 
different mutations in Clcn7. 
The p.G213R allele has been detected in several different families with Albers-Schönberg 
disease [11], but the p.F318L allele is less common. Nevertheless, the CLCN7 p.F318L 
mutation in humans is a bona fide osteopetrosis-causing mutation and the Clcn7
F318L
 allele in 
the mouse appears to recapitulate the human phenotype.  Mutant (p.F318L) CLC-7 protein 
likely inhibits the function of wild-type CLC-7 as a heterodimer. Although we have not 
formally demonstrated this in vitro or ex vivo, we conclude this is the case since Clcn7
F318L/+ 
mice have significantly increased BV/TV, which is not observed in mice that are 
heterozygous for a Clcn7 knockout (i.e., Clcn7
+/-
) mutation [23].  
Consistent with a previous report that used IFN-G in the Clcn7
G213R/+ 
mouse model [14] 
we found that IFN-G increased the CTX/TRAcP5b ratio, suggesting osteoclast function 
improves. Quantitative histomorphometry was not performed in the Clcn7
G213R/+
 mouse IFN-
G study, although an increase in osteoclast number was observed when this mouse model was 
first described and has also been reported in patients with Albers-Schönberg disease  [10, 32].  
Histomorphometric analyses in our Clcn7
F318L/+ 
mice also revealed an increased number of 
osteoclasts, that decreased in response to IFN-G treatment, consistent with the reduction in 
serum TRAcP5b levels. However, in contrast to Clcn7
G213R/+ 
mice, IFN-G did not increase 
CTX-I levels in Clcn7
F318L/+ 
mice, nor did it normalize BV/TV.  Thus, the putative effect of 
IFN-G on osteoclast function in Clcn7
F318L/+ 
mice is lower than that in Clcn7
G213R/+
 mice. 
The difference in the effectiveness of IFN-G in Clcn7
F318L/+ 
versus Clcn7
G213R/+
 mice may 
be explained by differences in how these two mutations impact CLC-7 trafficking and 
function. Cell transfection studies expressing mutant CLC-7 proteins indicate that some 
missense mutations cause retention of protein in the endoplasmic reticulum (ER) [6, 33], 
whereas other missense mutations do not affect localization but change channel activity [6]. 
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Cells expressing the p.G213R mutant CLC-7, retain the mutant protein in the endoplasmic 
reticulum [6, 33]. In contrast, cells expressing p.F318L mutant CLC-7 can transport the 
mutant protein to the lysosomal membrane where it is unable to produce plasma membrane 
current, suggesting that this mutation interferes with ion transport but not protein trafficking 
[6].  Thus, if IFN-G worked by improving CLC-7 channel trafficking in osteoclasts, it could 
benefit Clcn7
+/+
 and Clcn7
G213R/+ 
mice by allowing protein to reach the ruffled membrane 
more efficiently. In Clcn7
G213R/+
 mice, this would reduce the retention of mutant protein in 
the ER. Since CLC-7 dimers in Clcn7
F318L/+
 mice do not appear to have a trafficking problem, 
IFN-G therapy would not be expected to have the same degree of benefit in these animals.   
IFN-G is a cytokine that plays a critical role in both innate and adaptive immune 
responses, and is produced by natural killer (NK), NK T cells, CD4 and CD8 cells [34]. In 
1995 this drug showed some benefit in severe osteopetrosis patients [13] and, in a case report, 
benefit in a patient with intermediate osteopetrosis [35].  However, whether benefit derives 
from IFN-G actions on osteoclasts remains uncertain. In vitro studies showed that osteoclasts 
from patients with osteopetrosis stimulated with IFN-G were larger and had increased TRAP 
expression [36]. However, when this experiment was performed using control osteoclasts, 
IFN-G inhibited osteoclast formation and lowered Cathepsin K mRNA expression [37]. 
Adding to these puzzling results, IFN-G Receptor 1 knockout mice display an osteoporotic 
phenotype associated with reduced mineral apposition and bone formation but also reduced 
markers of osteoclast activity [38]. Moreover, exogenous administration of IFN-G in 
ovariectomized mice increased BMD and bone strength, rescuing the disease [39]. Thus, the 
IFN-G effect on bone is not restricted to osteoclasts.  Histomorphometric analyses revealed 
an increased number of osteoclasts in Clcn7
F318L/+ 
mice compared to wildtype mice, as has 
been previously reported in the Clcn7
G213R/+
 mice and in patients with Albers-Schönberg 
disease [10, 32]. In Clcn7
F318L/+
 mice, IFN-G decreased osteoclast number, which is 
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consistent with the reduction in serum TRAcP5b levels we observed in treated mice. With 
respect to bone formation, Clcn7
F318L/+
 mice were not significantly different from wildtype 
mice, similar to what has been reported for Albers-Schönberg disease [40].  Although IFN-G 
therapy increased the active mineralizing surface in Clcn7
F318L/+
 mice, it decreased the 
mineral apposition rate. Overall there was no effect of IFN-G on bone formation, µCT 
measurements of BV/TV and the serum measurements of P1NP.  
Having a second mouse model with a dominant negative mutation in Clcn7 that impairs 
osteoclast function makes it possible in a pre-clinical model to understand how drugs that 
affect CLC-7 trafficking and/or function might affect bone properties in patients with Albers-
Schönberg disease.  
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Figure legends 
 
Figure 1. Generation of mice with a Clcn7
F318L 
knockin allele that is expressed and 
translated into protein.  
(A) Schematic depiction of the wildtype (wt) Clcn7 locus and the gene targeting construct 
(not drawn to scale) indicating the locations of PCR primers used to amplify DNA for the 
homologous recombination arms within the targeting vector (P1-P4) and to confirm correct 
targeting of the locus (P5-P8). The targeting construct includes a neomycin resistance 
cassette (Neo
R
) flanked by loxP sites for positive selection, the p.F318L mutation in exon 11 
(*), and a thymidine kinase (TK) cassette for negative selection. After achieving germline 
transmission, the Neo
R
 cassette was removed by Cre-recombination. The bottom schematic 
depicts the mutant Clcn7 locus used in all animal experiments, with the location of primers 
(P9 and P10) used for genotyping indicated. (B) Representative image of a genotyping gel 
showing a 407 bp wildtype amplimer and a 530 bp mutant amplimer. (C) Sequencing 
electropherogram of PCR amplimer generated from a Clcn7
F318L/+
 mouse confirming 
heterozygosity for the TC transition. (D) RT-PCR using RNA from Clcn7+/+, Clcn7F318L/+ 
and Clcn7
F318L/F318L
 tibial bone showing the expected 677 bp amplimer in each sample, with 
no evidence of altered splicing due to the Clcn7
F318L
 allele. (E) Bar graph depicting droplet 
digital PCR results using cDNA from Clcn7
+/+
, Clcn7
F318L/+
 and Clcn7
F318L/F318L
 tibial bone 
showing the percentage of droplets than contain mutant or wildtype amplimers. Samples from 
3 mice with each genotype were studied, and ddPCR reactions were performed in duplicate. 
An average of 163 amplimer containing droplets were detected per reaction. (F) Fluorescence 
photomicrographs of cultured bone marrow cells isolated from Clcn7
+/+
 and Clcn7
F318L/F318L
 
mice that had been incubated with an anti-CLC-7 primary antibody and a FITC-labeled 
(green fluorescence) secondary antibody. Nuclei were stained with Hoechst 33342 dye and 
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fluoresce blue. Note Clcn7
+/+
 and Clcn7
F318L/F318L
 cells have similar patterns of CLC-7 
immunofluorescence. Importantly, in the absence of primary antibody, these 
immunofluorescence signals were not observed in these cells (data not shown). Scale bar 
equals 10 m. 
 
Figure 2. Twelve-week-old Clcn7
F318L/+ 
mice have a skeletal phenotype. 
(A) Bar graphs indicating the mean (±1SD) weight, bone mineral density (BMD), and bone 
mineral content (BMC) of 12-week-old female and male Clcn7
+/+
 (wt) and Clcn7
F318L/+ 
(het) 
mice. (B) Representative reconstructed microCT cross sectional images of midshaft and 
distal femur, and coronal images of the distal femur in wt and het mice. Bar graphs 
indicating mean (±1SD) values for wt and het mouse trabecular bone volume fraction 
(BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), trabecular separation 
(Tb.Sp), cortical area fraction (Ct.Ar/Tt.Ar) and cortical thickness (Ct.Th). Note that 
trabecular bone values are significantly affected by the Clcn7
F318L
 allele, whereas cortical 
bone values are only affected in males. (C) Bar graphs indicating mean (±1SD) 
biomechanical values for female and male wt and het
 
mouse femurs measured during three-
point bending. The Clcn7
F318L
 allele was not associated with significant differences in any 
measured value in females, however, males showed a decrease in energy to ultimate force. In 
all panels, values above the graphs are ANOVA and Bonferroni corrected p values, and 
values below the graphs indicate the number of animals studied in each cohort. 
 
Figure 3. A skeletal phenotype is detectable in 3-week-old Clcn7
F318L/F318L 
mice, but not 
in Clcn7
F318L/+
 mice.  
(A) Bar graphs indicating the mean (±1SD) weight and bone mineral density (BMD) in 3-
week-old female and male Clcn7
+/+
 (wt), Clcn7
F318L/+ 
(het), and Clcn7
F318L/F318L
 (hom) mice. * 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 26 
above the bars represent significant p values for wt vs. hom and het vs. hom comparisons 
calculated using ANOVA and Bonferroni correction, and values below the graphs indicate 
the number of animals studied in each cohort. (B) Representative reconstructed CT cross 
sectional images of midshaft and distal femur, and coronal images of the entire femur in wt, 
het, and hom mice.   
 
Figure 4. IFN-G does not improve bone properties in Clcn7
F318L/+
 mice. 
Bar graphs indicating the mean (±1SD) weight, bone mineral density (BMD), and trabecular 
bone volume fraction (BV/TV) by CT of 12-week-old female and male Clcn7+/+ (wt) and 
Clcn7
F318L/+ 
(het) mice that received vehicle (-) or IFN-G (+) from 4 to 12 weeks of age. As 
previously observed (see Figure 2) BV/TV is significantly increased in het compared to wt 
mice. However, IFN-G treatment did not affect BV/TV in mice with either genotype. Values 
below the graphs indicate the number of animals studied in each cohort.  
 
Figure 5. IFN-G decreases osteoclast surface and bone turnover in Clcn7
F318L/+
 mice. 
(A) Representative photomicrographs of bone sections stained for TRAP from 12-week-old 
male Clcn7
+/+
 (wt) and Clcn7
F318L/+ 
(het) mice that received vehicle (-) or IFN-G (+) from 4 to 
12 weeks of age. (B) Bar graphs indicating mean (±1SD) values for number of osteoclast per 
bone perimeter (N.Oc/B.Pm), osteoclast surface (N.Oc/BS), number of osteoblast per bone 
perimeter (N.Ob/B.Pm) and osteoblast surface (N.Ob/BS) in wt and het male mice. Note that 
osteoclast parameters are significantly affected by the Clcn7
F318L
 allele and normalize with 
treatment with IFN-G. (C) Representative photomicrographs of dual fluorochrome (calcein 
and alizarin red complexome) labeled distal femur metaphysis from 12-week-old male wt and 
het mice that received vehicle (-) or IFN-G (+) from 4 to 12 weeks of age. (D) Bar graphs 
indicating mean (±1SD) values for mineralizing surface (MS/BS), mineral apposition rate 
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(MAR), bone formation rate (BFR/BS) and bone turnover rate (BFR/BV) in wt and het male 
mice.  Note that MS/BS, MAR and BFR/BV are affected by IFN-G treatment, which can be 
appreciated in the photomicrographs (distance between the red and green labels in the close-
up panels). The increase in trabecular bone fraction among het mice is also visible.  (E) Bar 
graphs depicting the mean (±1SD) serum values of procollagen type 1 N terminal propeptide 
(P1NP), an indicator of bone anabolism, tartrate resistant acid phosphatase 5b (TRAcP 5b), 
an indicator of osteoclast number, and C terminal telopeptide of type 1 collagen (CTX-I), an 
indicator of osteoclast mediated bone catabolism. Only TRAcP 5b levels were significantly 
increased in both male and female het mice compared to sex-matched wt mice, and 
significantly reduced in het mice that received IFN-G. However, IFN-G treatment did not 
significantly affect the bone catabolic marker CTX-I or the bone anabolic marker P1NP in 
both males and females. In all panels, values above the graphs are ANOVA and Bonferroni 
corrected p values, and values below the graphs indicate the number of animals studied in 
each cohort. 
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Fig. 1 
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Fig. 2 
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Fig. 4 
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Fig. 5 
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Highlights 
 
 A new model of Albers-Schönberg disease has been created with Clcn7F318L/+ mice. 
 Clcn7F318L/+ mice have increased numbers of osteoclasts and increased trabecular bone 
volume when compared to Clcn7
+/+
 littermates. 
 Interferon-gamma treatment of Clcn7F318L/+ mice normalized the number of osteoclasts, 
but had no effect on trabecular bone volume. 
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